President Donald Trump’s executive order to fund research into psychedelic therapies and fast-track their review has been widely lauded, and for good reason. Drugs such as psilocybin and MDMA have demonstrated striking results in clinical trials to treat depression, post-traumatic stress disorder and other serious mental health conditions. The order injects momentum into this burgeoning field and opens the door for eager patients to try these therapies.

© Washington Post